Showing results (331-340 of 425) with videos related to

Sort By:
Pageof 43
Cancer|August 30, 2024
Generative artificial intelligence as a source of breast cancer information for patients: Proceed with cautionKo Un Park, Stuart Lipsitz, Laura S Dominici, et al.
Breast Cancer Research and Treatment|March 7, 2012
Biologic features and prognosis of ductal carcinoma in situ are not adversely impacted by initial large body massHenry M Kuerer, Sara A Lari, Banu K Arun, et al.
NPJ Breast Cancer|August 26, 2021
Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker studyRomualdo Barroso-Sousa, Tanya E Keenan, Tianyu Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 3, 2024
A Phase II Study of Atezolizumab, Pertuzumab, and High-Dose Trastuzumab for Central Nervous System Metastases in Patients with HER2-Positive Breast CancerAntonio Giordano, Priya U Kumthekar, Qingchun Jin, et al.
NPJ Breast Cancer|April 16, 2024
Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancerStefania Morganti, Qingchun Jin, Julie Vincuilla, et al.
Cancer Immunology Research|May 6, 2017
4-1BB-Enhanced Expansion of CD8+ TIL from Triple-Negative Breast Cancer Unveils Mutation-Specific CD8+ T CellsMichiko Harao, Marie-Andrée Forget, Jason Roszik, et al.
Clinical Immunology (Orlando, Fla.)|January 24, 2021
Subgroup analysis of nelipepimut-S plus GM-CSF combined with trastuzumab versus trastuzumab alone to prevent recurrences in patients with high-risk, HER2 low-expressing breast cancerR Connor Chick, G Travis Clifton, Diane F Hale, et al.
Clinical Breast Cancer|August 6, 2018
Neoadjuvant Pertuzumab-containing Regimens Improve Pathologic Complete Response Rates in Stage II to III HER-2/neu-positive Breast Cancer: A Retrospective, Single Institution ExperienceRashmi K Murthy, Akshara S Raghavendra, Kenneth R Hess, et al.
Annals of Surgical Oncology|August 27, 2013
Incidence and consequence of close margins in patients with ductal carcinoma-in situ treated with mastectomy: is further therapy warranted?Elizabeth Fitzsullivan, Sara A Lari, Benjamin Smith, et al.
Annals of Surgical Oncology|November 23, 2025
Axillary Management and Outcomes After Neoadjuvant Endocrine Therapy in the Randomized PELOPS TrialAnna Weiss, Qingchun Jin, Nabihah Tayob, et al.
Pageof 43